Division of Molecular Pathology, The Institute of Cancer Research, London, United Kingdom. Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.
Structural Genomics Consortium, University of Oxford, Oxford, United Kingdom.
Cancer Res. 2014 Sep 1;74(17):4565-70. doi: 10.1158/0008-5472.CAN-14-1298. Epub 2014 Aug 18.
Whole-genome sequencing studies have recently identified a quarter of cases of the rare childhood brainstem tumor diffuse intrinsic pontine glioma to harbor somatic mutations in ACVR1. This gene encodes the type I bone morphogenic protein receptor ALK2, with the residues affected identical to those that, when mutated in the germline, give rise to the congenital malformation syndrome fibrodysplasia ossificans progressiva (FOP), resulting in the transformation of soft tissue into bone. This unexpected link points toward the importance of developmental biology processes in tumorigenesis and provides an extensive experience in mechanistic understanding and drug development hard-won by FOP researchers to pediatric neurooncology. Here, we review the literature in both fields and identify potential areas for collaboration and rapid advancement for patients of both diseases.
全基因组测序研究最近发现,四分之一的罕见儿童脑干肿瘤弥漫性内在脑桥神经胶质瘤病例携带体细胞突变的 ACVR1。该基因编码 I 型骨形态发生蛋白受体 ALK2,受影响的残基与那些在种系中发生突变导致先天性畸形综合征纤维发育不良性骨化进展(FOP)的残基相同,导致软组织转化为骨。这一意外联系指向了发育生物学过程在肿瘤发生中的重要性,并为儿科神经肿瘤学提供了 FOP 研究人员在机制理解和药物开发方面来之不易的广泛经验。在这里,我们回顾了这两个领域的文献,并确定了这两种疾病患者合作和快速进展的潜在领域。